Bridging the academic and industry interface to satisfy unmet clinical need
Lead Research Organisation:
Cardiff University
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The MRC Proximity to Discovery scheme awards universities funds to help develop new collaborations, and ways of exchanging knowledge and skills. The awards can be used to support activities that promote the value of academic-industry partnership, and enhance academic and industry researchers’ understanding of each other’s needs and capabilities. This may be through people exchanges, creation of technology demonstrators, showcase events, commercialisation workshops and ‘entrepreneurs in residence’ schemes. Such exchanges of knowledge and skills will boost the most fruitful collaborations between UK universities and life science companies.
People |
ORCID iD |
| Description | ASTUTE 2020 |
| Amount | £40,000 (GBP) |
| Organisation | European Commission |
| Department | Horizon 2020 |
| Sector | Public |
| Country | European Union (EU) |
| Start | 12/2017 |
| End | 11/2018 |
| Description | Continuity Grant |
| Amount | £23,000 (GBP) |
| Organisation | Galecto Biotech |
| Sector | Private |
| Country | Sweden |
| Start | 03/2017 |
| End | 10/2017 |
| Description | Industry Sponsored Studentship |
| Amount | £110 (GBP) |
| Organisation | Galecto Biotech |
| Sector | Private |
| Country | Sweden |
| Start | 10/2017 |
| End | 09/2021 |
| Description | AML Biomarker collaboration |
| Organisation | Medical Research Council (MRC) |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | MRC Clinical Proteomics Centre for Stratified Medicine - SWATH MS is a new technology and its application of this to biomarker discovery is still in its infancy. This project has helped to develop new technical refinements and analytical approaches. |
| Collaborator Contribution | The newly created Clinical Proteomics Centre for Stratified Medicine is a £12M investment by the MRC to create a world-leading facility for clinical proteomics. A key objective of the Centre is the pragmatic discovery of novel protein biomarkers to allow stratification of patients according to their disease endotype. |
| Impact | Approximately 96 plasma samples from intermediate risk patients were separated into good and poor outcome groups and analysed by SWATH MS which uses mass spectrometry and a peptide library to identify differences in protein composition between the 2 groups. All samples were run in triplicate;81 of the samples passed QC. Initial models suggest reasonable accuracy (70 - 80%) of identifying good outcome patients using Random Forest machine learning |
| Start Year | 2017 |
| Description | Collaborative Partnership |
| Organisation | Nexcelom Bioscience LLC |
| Country | United States |
| Sector | Private |
| PI Contribution | allowed us to conduct industrial-level screens of spheroids of cell lines (standards) and patient derived Mesenchymal Stem Cells. |
| Collaborator Contribution | they brought their instrument to Cardiff for two weeks, with senior scientist. This new partner provided a screening imaging platform |
| Impact | Publications in press |
| Start Year | 2017 |
| Description | Reneuron |
| Organisation | Reneuron |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Exosome labelling optimisation and glioma model production |
| Collaborator Contribution | bio-distribution of ReNeuron's exosomes; and also the investigation of radio-labelled exosomes and their use as PET imaging agents. |
| Impact | in progress |
| Start Year | 2017 |
| Description | Boston CYTO2017 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Boston CYTO2017 |
| Year(s) Of Engagement Activity | 2017 |
| Description | Infection Control Presentation |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Infection Control and Prevention Conference in Geneva in June 2017. Interest in the MRC P2D study was expressed by the World Health Organization |
| Year(s) Of Engagement Activity | 2017 |